Studies on levamisole--induced agranulocytosis

Area of Science:

• Immunology
• Hematology
• Pharmacology

Background:

• Levamisole is used as an immunopotentiator in various conditions.
• Levamisole treatment is associated with a significant risk of agranulocytosis (AGC).
• The exact mechanism behind levamisole-induced AGC remains largely unknown.

Purpose of the Study:

• To investigate the pathogenesis of levamisole-induced agranulocytosis.
• To identify potential diagnostic markers for predicting AGC onset.

Main Methods:

• Serum from neutropenic patients was tested using fluorochromatic microgranulocytotoxicity (GCY) assays.
• Antibody characterization included testing against granulocytes, lymphocytes, monocytes, and cell lines.
• Leukoagglutination tests and in vitro mixing experiments were performed.

Main Results:

• GCY tests were positive in 10 out of 10 patients with acute neutropenia.
• The identified antibody was IgM and reacted broadly with granulocytes.
• GCY positivity preceded AGC onset by 2-3 months in two patients.

Conclusions:

• Levamisole-induced AGC may involve an antibody targeting granulocytes.
• The GCY assay shows potential for early detection of patients at risk for AGC.
• Further research could lead to predictive strategies for levamisole-induced neutropenia.